StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $8.58 | $8.53 | -0.58% | 0.3M |
| 05-12 | $8.36 | $8.70 | +4.07% | 0.1M |
| 05-13 | $8.62 | $8.42 | -2.32% | 0.1M |
| 05-14 | $8.49 | $8.27 | -2.59% | 0.1M |
| 05-15 | $8.21 | $7.38 | -10.11% | 0.1M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
No sell-side coverage available for RNAC.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for RNAC.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $400.00K | $400.00K | $400.00K |
Operating Income | $-26.50M | $-143.41M | $-64.77M | $-43.70M |
Net Income | $-39.18M | $-130.30M | $-37.73M | $15.89M |
EPS (Diluted) | $-1.46 | $-5.02 | $-1.45 | $-0.07 |
Total Assets | $288.39M | $296.41M | $372.68M | $388.89M |
Total Liabilities | $436.51M | $422.65M | $408.52M | $391.42M |
Cash & Equivalents | $118.64M | $125.14M | $143.38M | $160.32M |
Free Cash Flow OCF − CapEx | $-22.16M | $-79.39M | $-61.19M | $-44.30M |
Shares Outstanding | 28.54M | 26.01M | 26.00M | 26.00M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.